Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Innate Pharma (IPHYF) Non Operating Income (2020 - 2022)

Historic Non Operating Income for Innate Pharma (IPHYF) over the last 2 years, with Q4 2022 value amounting to -$557.06.

  • Innate Pharma's Non Operating Income changed N/A to -$557.06 in Q4 2022 from the same period last year, while for Dec 2022 it was -$6.7 million, marking a year-over-year change of. This contributed to the annual value of $2.2 million for FY2024, which is 5901.87% down from last year.
  • Latest data reveals that Innate Pharma reported Non Operating Income of -$557.06 as of Q4 2022.
  • Innate Pharma's 5-year Non Operating Income high stood at -$557.06 for Q4 2022, and its period low was -$2.3 million during Q4 2020.